GlaxoSmithKline Tesaro’yu yaklaşık nakit 5.1 milyar dolara satın alma konusunda anlaşmaya vardı.
GSK’dan yapılan açıklamaya göre, satın alma fiyatı nakit hisse başına 75 dolar olacak ve bu, Tasaro’nun 30 günlük işlem hacmi ağırlıklı ortalama fiyatı olan 35.67 doların yüzde 110 primli seviyesini işaret ediyor.
GSK, Tesaro ve bağlı Ar-Ge ve ticari yatırımlarının satın alınmasının önümüzdeki iki yılda düzeltilmiş hisse başına karı yüzde 5 ila 9 arası etkilemesini bekliyor.
GFK, 2018 yılının tüm yıl için düzeltilmiş hisse başına karı için artış tahminini değiştirmeyerek yüzde 8 ila 10 aralığında bıraktı.
Emma Walmsley, Chief Executive Officer, GSK, said: “The acquisition of TESARO will strengthen our pharmaceuticals business by accelerating the build of our oncology pipeline and commercial footprint, along with providing access to new scientific capabilities. This combination will support our aim to deliver long-term sustainable growth and is consistent with our capital allocation priorities. We look forward to working with TESARO’s talented team to bring valuable new medicines to patients.”
Hal Barron, Chief Scientific Officer and President, R&D, GSK, said: “Our strong belief is that PARP inhibitors are important medicines that have been under appreciated in terms of the impact they can have on cancer patients. We are optimistic that Zejula will demonstrate benefit in patients with ovarian cancer beyond those who are BRCA-positive as front-line treatment. We are also very excited that through this transaction, we will have the opportunity to work with an outstanding Boston-based oncology group with deep clinical development expertise and together we will explore Zejula’s efficacy beyond ovarian cancer into multiple tumour types to help many more patients.”
Lonnie Moulder, Chief Executive Officer, TESARO, said: “This transaction marks the beginning of a new global partnership that will accelerate our oncology business and allow our mission of delivering transformative products to individuals living with cancer to endure. Our Board and Management team are very pleased to announce this transaction, and we are grateful to the management team at GSK for their tremendous vision and the opportunity to preserve and build upon the impact we have had in the cancer community to date.”
Mary Lynne Hedley, President and Chief Operating Officer, TESARO, said: “This partnership marks an evolution in the way we live out the TESARO mission and will allow us to more rapidly deliver on our commitment to patients. I am excited to be partnering with our new colleagues at GSK as together we advance innovative scientific and drug development strategies that ultimately enable us to provide more time for more patients.”